PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
Last trade$0.9076
Day change-$0.0165 (-1.79%)
Day range$0.86 – $0.975
Volume2,401,179
Market cap$113M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$112.89M
Price / earnings
—
Price / book
-31.54×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.02×
Profitability
Earnings per share
-$0.27
Return on assets
-382.32%
Return on equity
940.63%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.22×
Current ratio
0.57×
Quick ratio
0.57×
Cash ratio
0.45×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.78M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PDSB, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.23M
$3.06M
$2.27M
$3.56M
$3.41M
$3.27M
$2.83M
$3.37M
Research and development
$3.27M
$3.46M
$4.41M
$4.58M
$4.21M
$5.83M
$4.53M
$6.8M
Total operating expenses
$6.5M
$6.52M
$6.67M
$8.14M
$7.62M
$9.11M
$7.36M
$10.18M
Operating income
-$6.5M
-$6.52M
-$6.67M
-$8.14M
-$7.62M
-$9.11M
-$7.36M
-$10.18M
Interest expense
-$3.38M
-$1.01M
-$1.11M
-$1.15M
-$2.14M
-$930.88K
-$1.1M
-$1.21M
Income before taxes
-$9.75M
-$7.35M
-$7.56M
-$9.01M
-$9.43M
-$9.66M
-$7.95M
-$10.73M
Income taxes
$0
$0
$0
$0
$0
-$1.17M
$0
$0
Net income
-$9.75M
-$7.35M
-$7.56M
-$9.01M
-$9.43M
-$8.49M
-$7.95M
-$10.73M
Net income attributable to common shareholders
-$9.75M
-$7.35M
-$7.56M
-$9.01M
-$9.43M
-$8.49M
-$7.95M
-$10.73M
EBITDA
-$6.49M
-$6.52M
-$6.67M
-$8.13M
-$7.62M
-$9.1M
-$7.36M
-$10.17M
Basic earnings per share
-$0.18
-$0.13
-$0.14
-$0.19
-$0.21
-$0.21
-$0.21
-$0.29
Diluted earnings per share
-$0.18
-$0.13
-$0.14
-$0.19
-$0.21
-$0.21
-$0.21
-$0.29
Recent news
Company coverage with links to the original publishers.
PDS Biotechnology (PDSB) has triggered a golden cross technical signal, with its 50-day moving average crossing above its 200-day moving average. The stock has rallied 34.9% over the past four weeks and holds a #3 (Hold) Zacks Rank. Earnings estimates have also moved higher, with one upward revision in the past 60 days, suggesting potential for a bullish breakout.
PDS Biotechnology Corporation announced the appointment of John Dawson CBE, Deborah Ramsdell, and Bruce Wendel to its Board of Directors effective October 18, 2026. The three executives bring extensive experience in drug development, commercialization, and regulatory affairs. The appointments follow the resignations of four board members. The company is advancing PDS0301 toward Phase 3 trials in metastatic colorectal cancer and pursuing partnerships for PDS0101.
PDS Biotechnology has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates over the past three months, which increased by 10.6%. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improved earnings outlook.
The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.
The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.